small molecule

OLUX

CLOBETASOL PROPIONATE

Loss of exclusivityloss of exclusivity
CompanyPHARMOBEDIENT CONSULTING LLC

Drug detail

Brand nameOLUX
Active ingredientCLOBETASOL PROPIONATE
Strength0.05% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Dosage formAEROSOL, FOAM
RouteTOPICAL
ModalitySmall molecule
FDA approvalMay 2000
Marketing statusDISCN

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

OLUX patent cliff — loss of exclusivity — | CliffBio